General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -0.13 | -0.13 | N/A | N/A |
2024-02-07 | 2023-12 | -0.15 | -0.11 | 0.04 | 26.67% |
2023-11-27 | 2023-09 | -0.16 | -0.12 | 0.04 | 25.00% |
2023-08-08 | 2023-06 | -0.17 | -0.14 | 0.03 | 17.65% |
2023-05-09 | 2023-03 | -0.18 | -0.17 | 0.01 | 5.56% |
2023-02-07 | 2022-12 | -0.2 | -0.17 | 0.03 | 15.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-06-28 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-01 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-30 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-08 | BTIG | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-06-28 | BOENISCH SANDRA | Officer and Treasurer | 22.96K | Sale |
2021-05-16 | DONHAUSER PETER D.O. | Director | 2.17K | Purchase |
2021-05-20 | FAVUS ELLIOT J. M.D. | Director | 0.00 | Sale |
2012-05-28 | LALACH HARVEY | President | 550.00K | Sale |
2024-03-27 | MISSLING CHRISTOPHER U | Chief Executive Officer | 1.25M | Sale |
2022-05-24 | SKARPELOS ATHANASIOS | Director | 1.31M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 5.94M | 48.28M | 7.25% |
2023-06-29 | State Street Corporation | 4.41M | 35.84M | 5.38% |
2023-06-29 | Vanguard Group Inc | 4.20M | 34.18M | 5.13% |
2023-06-29 | Geode Capital Management, LLC | 1.54M | 12.54M | 1.88% |
2023-06-29 | Northern Trust Corporation | 735.99K | 5.98M | 0.90% |
2023-06-29 | NWAM LLC | 634.60K | 5.16M | 0.77% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.95M | 23.34M | 3.61% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.27M | 18.43M | 2.77% |
2023-08-30 | iShares Russell 2000 ETF | 1.61M | 12.72M | 1.96% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.10M | 8.94M | 1.34% |
2023-07-30 | Fidelity Small Cap Index Fund | 628.31K | 5.18M | 0.77% |
2023-08-30 | iShares Russell 2000 Growth ETF | 590.24K | 4.66M | 0.72% |
Split | Date |
---|---|
1 : 4 | 2015-10-07 |
I don't think the Journal article is needed for EMA. FdA I think it would be. FDA is in bed with big pharma and a published article would exert maximum pressure. Things look terrible for the FDA IRT Alzheimer's. They might be ready to put the beta amyloid baby to bed. If so things could move faster. Generally speaking an article would be the best way to move forward.
If you were a small gold mining operation and struck the mother load would you go running in to town and tell everyone? If you were smart you would makes sure that everything was iron clad With all the i's dotted and t's crossed. Good way to lose everything would be to run around telling everyone. Big Bio, Wallstreet are ruthless Chris knows this. Its not by chance you have bashers here. They want your shares. Everyone on this board has an agenda, period, full stop. Read the studies and presentations and make your own decision. I have made mine.
As you said the corruption is the reason why we are keeping cards held close and why we are filing with the EMA first. Says to the FDA that if they fuck around and the drug gets approved in europe while making AVXL jump through hoops there is going to be explaining to do to congress. This is a paradigm shift in the treatment of neurological diseases. Makes sense that AVXL would not do anything to piss off the FDA or give the shorts any oppertunity to cover. I know what I own
Data being held for peer review inorder to crush the shorts. We know there were super responders. Likely some of them are considered cured. Please tell me any other drug for ALZ that has super responders!?... Zero. Shorts areFe'd 25% of float is short.
If this was such dog sh!+ why is this ticker consistently one of the most active on the the message boards? The potential revenue is astronomical. Everyone on this board has an agenda. Anyone claiming to give advice on buying or selling as your best interest is full of crap. Look at the science and make your own decision. This is biotechnology investing. If you dont know what you own you shouldn't be investing.
Lots of folks hear trying to convince everyone that the company is crap. So nice of them to look out for all of us. Makes me have hope for mankind that there are people out there willing to hunt down crap companies and post daily so they can save us all. I think I will sell all my shares now..
So you are saying CM would lie about speaking to the EMA? The Fbagstien might be right? Yes CM is hiding something. The full results that will be published in a Journal article so that shorts get fried. This is common knowledge. You think CM controls the EMA? You think he can tell a major Journal when to publish an article? lThis is a new MOA. A paradigm shift in the treatment of ALZ patients. You want the data in advance so you can spin it in a negative light. Cover your short position soon. Your soft bashing isn't convincing anyone. AF is a scumbag. When the full data comes out all his friends are going to get fried.
Super excited for what we hear from the FDA. I would think that because of the good results and the outstanding safety that we get Fast Track. The EMA filing first was a smart move. How would it look if the EMA approval happens first yet the FDA makes AVXL jump through hoops for ALZ that has basically no effective treatment. They would be dragged before congress and have some serious explaining to do if full results support what we already know.